Dingxin recipe Ⅲ ameliorates hyperlipidemia injury in SD rats by improving the gut barrier, particularly the SCFAs/GPR43 pathway

• Published in: Journal of ethnopharmacology 2023-08, Vol.312, p.116483-116483, Article 116483
• Main Authors: Gu, Yu-yan, Cui, Xiao-bing, Jiang, Jing, Zhang, Ya-xin, Liu, Meng-hua, Cheng, Sai-bo, Li, Yu-ye, Liu, Lin-ling, Liao, Rong-xin, Zhao, Peng, Jin, Wen, Jia, Yu-hua, Wang, Jing, Zhou, Feng-hua
• Format: Article
• Language: English
• Subjects: Animals; DXR; Fatty Acids, Volatile - metabolism; Gut microbiota; Hyperlipidemia; Hyperlipidemias - drug therapy; Lipid metabolism; Lipids; Rats; Rats, Sprague-Dawley; SCFAs; Tandem Mass Spectrometry
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/j.jep.2023.116483

Dingxin Recipe Ⅲ (DXR Ⅲ) is a traditional Chinese medicine compound used for hyperlipidemia treatment in clinical practice. However, its curative effects and pharmacological mechanisms in hyperlipidemia have not been clarified to date. Studies have demonstrated that gut barrier was strongly implicated in lipid deposition. Based on gut barrier and lipid metabolism, this study examined the effects and molecular mechanisms of DXR Ⅲ in hyperlipidemia. The bioactive compounds of DXR Ⅲ were detected by ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry, and its effects were evaluated in high-fat diet-fed rats. Specifically, the serum levels of lipids and hepatic enzymes were measured using the appropriate kits; colon and liver sections were obtained for histological analyses; gut microbiota and metabolites were analyzed by 16S rDNA sequencing and liquid chromatography-MS/MS; and the expression of genes and proteins was determined by real-time quantitative polymerase chain reaction and western blotting and immunohistochemistry, respectively. The pharmacological mechanisms of DXR Ⅲ were further explored by fecal microbiota transplantation and short-chain fatty acid (SCFAs)-based interventions. DXR Ⅲ treatment significantly downregulated serum lipid levels, mitigated hepatocyte steatosis and improved lipid metabolism. Moreover, DXR Ⅲ improved the gut barrier, specifically by improving the physical barrier in the colon, causing part composition changes in the gut microbiota, and increasing the serum SCFAs level. DXR Ⅲ also upregulated the expression of colon GPR43/GPR109A. Fecal microbiota transplantation from rats treated with DXR Ⅲ downregulated part hyperlipidemia-related phenotypes, while the SCFAs intervention significantly improved most of the hyperlipidemia-related phenotypes and upregulated the expression of GPR43. Moreover, both DXR Ⅲ and SCFAs upregulated the expression of colon ABCA1. DXR Ⅲ protects against hyperlipidemia by improving the gut barrier, particularly the SCFAs/GPR43 pathway. [Display omitted] •This study examined the effects of Dingxin Recipe Ⅲ in hyperlipidemia based on gut barrier and lipid metabolism.•Mechanisms of Dingxin Recipe Ⅲ were explored by fecal microbiota transplantation and short chain fatty acid intervention.•Dingxin Recipe Ⅲ improved HFD-induced hyperlipidemia and gut barrier, including physical barrier, gut microbiota, and SCFAs.•Dingxin Recipe Ⅲ protects against hyperlipidemia by improv